Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ORKABullishCorporate Developmentsnews

High materiality8/10

Phase 2b results bolster ORKA-001 Phase 3 plans in 2027

Oct 26, 2026, 1:25 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 2b efficacy with clear dose-response and ongoing Phase 3 planning typically drives near-term reratings for biotech names; however, ultimate upside hinges on Phase 3 outcomes and regulatory timing.

AI summary

What happened, with direct paths to the underlying reporting

Oruka Therapeutics reported positive Week 16 results from EVERLAST-B for ORKA-001 in moderate-to-severe plaque psoriasis, with the 600 mg high-dose achieving 61% PASI-100 and strong PASI-90 outcomes. The company plans Phase 3 trials in early 2027 and expects 52-week data from EVERLAST-A in December 2026, setting up near-term catalysts and mid-term upside tied to regulatory progress.

Phase 2b EVERLAST-B shows strong efficacy versus placebo at Week 16.
600 mg high dose achieves dose-dependent skin clearance.
Safety aligns with IL-23p19 class; adverse events similar to placebo.
Regulatory discussions target Phase 3 start in H1 2027.
52-week data from EVERLAST-A due December 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Phase 2b results bolster ORKA-001 Phase 3 plans in 2027

Oruka's ORKA-001 Shows Durable Psoriasis Efficacy; Long-Term Data Ahead in 2026

ORKA Reports Promising Phase 1 Results with Significant Skin Clearance